Deals Of The Week: How Do 2013 Biotech Deal Stats Stack Up After Amgen/Onyx?
Executive Summary
A busy summer of biotech acquisitions, including the pricey buyouts of Onyx by Amgen and Elan by Perrigo, has lifted the number of U.S. public biotech acquisitions so far in 2013 – and increased the average value of those deals. In other deal news, Endo plans to acquire Boca Pharmacal, Medimmune will buy out Amplimmune, and Eli Lilly signed a diabetes research deal with Zealand Pharma.
You may also be interested in...
Amgen Wins Onyx, But Will The Deal Pave The Road To Transformation?
The addition of Onyx’s cancer drugs to Amgen’s portfolio will fill a near-term sales gap for the big biotech and reinforce the company as a major oncology player. But Amgen will need to execute expertly on the merger if it is to transform itself into a high-growth biotech.
Sangamo Adds To Its Own Gene Therapy Technology With Ceregene Buy
The biotech will bolster its own internal programs, as well as gain a potentially lucrative mid-stage asset through the acquisition, with no effect on its own balance sheet.
Ophthalmology M&A Engine Keeps Roaring As Akorn Buys Out Hi-Tech
CEO Raj Rai calls the transaction a “transformative event” for Akorn that will be instantly accretive and produce between $15 million and $20 million of run-rate synergies within 12 months. Acquisition of Hi-Tech adds prescription and OTC products, 18 filed ANDAs and increased manufacturing capability.